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Abstract
Despite the development of new targeted and immune therapies, the prognosis of metastatic melanoma remains bleak.
Therefore, it is critical to better understand the mechanisms controlling advanced melanoma to develop more effective
treatment regimens. Hedgehog/GLI (HH/GLI) signaling inhibitors targeting the central pathway transducer Smoothened
(SMO) have shown to be clinical efficacious in skin cancer; however, several mechanisms of non-canonical HH/GLI
pathway activation limit their efficacy. Here, we identify a novel SOX2-BRD4 transcriptional complex driving the
expression of GLI1, the final effector of the HH/GLI pathway, providing a novel mechanism of non-canonical SMO-
independent activation of HH/GLI signaling in melanoma. Consistently, we find a positive correlation between the
expression of GLI1 and SOX2 in human melanoma samples and cell lines. Further, we show that combined targeting of
canonical HH/GLI pathway with the SMO inhibitor MRT-92 and of the SOX2-BRD4 complex using a potent Proteolysis
Targeted Chimeras (PROTACs)-derived BRD4 degrader (MZ1), yields a synergistic anti-proliferative effect in melanoma
cells independently of their BRAF, NRAS, and NF1 mutational status, with complete abrogation of GLI1 expression.
Combination of MRT-92 and MZ1 strongly potentiates the antitumor effect of either drug as single agents in an orthotopic
melanoma model. Together, our data provide evidence of a novel mechanism of non-canonical activation of GLI1 by the
SOX2-BRD4 transcriptional complex, and describe the efficacy of a new combinatorial treatment for a subset of melanomas
with an active SOX2-BRD4-GLI1 axis.
Introduction
Melanoma is the most aggressive form of skin cancer and
its incidence is increasing worldwide. Genetic alterations in
BRAF and NRAS, as well as a handful of tumor suppressors
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shown to contribute to melanoma pathogenesis [1, 2].
Aberrant activation of oncogenic BRAF has provided the
basis for targeted therapy with specific inhibitors of mutant
BRAF and MEK, although the long-term clinical benefits of
these treatments are hampered by the development of drug
resistance. Immune checkpoint inhibitors have shown more
durable responses, although response rate still remains low
[3]. Therefore, there is a need for novel treatments for
relapsed or refractory melanoma patients based on new
knowledge driving advanced stages of the disease.
Canonical Hedgehog/GLI (HH/GLI) signaling is trig-
gered by binding of HH ligands to the twelve-pass trans-
membrane receptor Patched 1 (PTCH1). As such, PTCH1
no longer represses the seven-pass transmembrane G
protein-coupled receptor Smoothened (SMO), allowing the
intracellular activation of the zinc finger transcription
factor GLI2, which translocates into the nucleus and
transactivates GLI1 promoter. Aberrant activation of HH/
GLI signaling occurring in a variety of cancers leads to the
activation of GLI transcription factors, which initiate and
promote tumor growth by continuous transactivation of
HH target genes [4]. Several studies have also reported
non-canonical mechanisms of GLI activation in cancer,
which may occur independent of upstream PTCH/SMO
signaling [5]. Small molecule inhibitors targeting SMO
have demonstrated therapeutic efficacy in advanced basal
cell carcinoma (BCC) [6]. However, the successful clinical
use of SMO antagonists is challenged by development of
acquired resistance, severe adverse effects and relapse of
patients upon drug withdrawal. Preclinical studies have
shown the efficacy of SMO inhibition in reducing tumor
burden in melanoma [7–9]. For example, the potent acyl-
guanidine derivative targeting SMO (MRT-92) has shown
good results in decreasing human melanoma xenograft
growth in vivo [10]. Although MRT-92 appears a pro-
mising candidate for future clinical studies, interference
with SMO alone may not be effective in blocking HH
signaling in cancers having canonical and non-canonical
HH/GLI signaling activation, such as melanoma. Only
targeting non-canonical HH/GLI pathway is predicted to
improve the response rates and durability of therapeutic
effects exerted by SMO inhibitors. Thus, it is critical to
investigate mechanisms of HH/GLI pathway activation
downstream of SMO, especially those occurring at the
transcriptional level.
In this study, we identify a novel BRD4-SOX2 transcrip-
tional complex responsible for non-canonical activation of
GLI1 in melanoma. We provide evidence that the chromatin
reader BRD4 [11, 12] acts as cofactor of SOX2 to control
GLI1 promoter activity and expression. Combination of MZ1,
a potent BRD4 degrader designed using the Proteolysis
Targeted Chimeras (PROTACs) technology [13, 14], with the
SMO inhibitor MRT-92 yields a synergistic reduction of
melanoma cell growth in vitro and in vivo, providing a
rationale for a novel therapeutic approach in melanoma.
Results
SOX2 modulates HH/GLI signaling by inducing non-
canonical activation of GLI1
Transcriptional activation of GLI1 independent of upstream
SMO is one of the major driver of non-canonical activation
of the HH/GLI pathway [5]. In silico analysis of GLI1 pro-
moter (obtained from the UCSC Genome Browser assembly
ID:hg38) (Supplementary Fig. 1) using the TFBIND bioin-
formatics software (http://tfbind.hgc.jp) revealed significant
enrichment of binding motifs (wwTGnwTw) [15] for SOX2
(Fig. 1A), a well characterized transcription factor involved
in stemness, drug resistance, and tumor growth [16]. Chro-
matin Immunoprecipitation (ChIP) using anti-SOX2 anti-
body followed by quantitative real-time PCR (qPCR) with
primers spanning different regions of GLI1 promoter
revealed SOX2 occupancy close to GLI1 transcription start
site (TSS) (region A) with more than tenfold enrichment
in GLI1 signal over ChIP with an isotype IgG (p < 0.01)
(Fig. 1A). To investigate the regulation of GLI1 by SOX2,
we first tested the effect of SOX2 silencing on the expression
of GLI1. Depletion of SOX2 using two independent shRNAs
significantly decreased the expression of GLI1 mRNA and
protein in several melanoma cell types (Fig. 1B and C;
Supplementary Fig. 2). We next tested the effect of SOX2
modulation on the transcriptional activity of the endogenous
HH/GLI signaling. While SOX2 silencing led to a significant
reduction of GLI-dependent luciferase reporter activity, its
ectopic expression strongly increased it (Fig. 1D). Silencing
of GLI1, but not that of SMO, was able to partially revert the
effect of SOX2 overexpression on the reporter activity,
confirming that SOX2 regulates HH/GLI pathway down-
stream of SMO (Fig. 1D).
To identify the site responsible for the modulation by
SOX2, we cloned the following regions of the GLI1 pro-
moter upstream a luciferase gene: the GLI1 proximal pro-
moter (−829/+111 bp from TSS) containing six potential
SOX2 binding sites (BS) and a canonical GLI-BS close to
TSS; the−829/−133 bp region of the GLI1 promoter lacking
the GLI-BS; and the −584/−133 bp region containing only
three putative SOX-BS (Fig. 1E). All three promoters
showed similar basal activity in melanoma cells (Supple-
mentary Fig. 3). Patient-derived SSM2c melanoma cells
were transfected with the reporter along with SOX2 or GLI1.
Luciferase assay showed that SOX2 transactivated all three
regions (Fig. 1E), excluding the involvement of GLI1 on
self-transactivation and narrowing the presence of a func-
tional SOX2-BS in the three sites proximal to the GLI1 TSS.
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To precisely map the SOX2-BS, we mutated each consensus
sequences identified in the −584/−133 bp fragment in two
crucial positions for the efficiency of SOX2 binding
(Fig. 1F). Disruption of site2 (−584 mut2), but not that of
site1 (−584 mut1) nor site3 (−584 mut3) prevented the
transactivation of GLI1 by SOX2 (Fig. 1G), indicating that
SOX2 transactivates GLI1 by direct binding to the consensus
sequence CTTGGATT in GLI1 proximal promoter.
In support of the biological relevance of the transcrip-
tional regulation of GLI1 by SOX2, we found a statistically
significant correlation between SOX2 and GLI1 expression
in a panel of metastatic melanoma cells (Pearson score
R= 0.664, p= 0.036) (Fig. 1H; Supplementary Fig. 4a).
Furthermore, comparison of GLI1 and SOX2 expression
levels in 477 TCGA melanoma patients showed a co-
expression of these two transcripts (p < 0.0001) (Fig. 1I)
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and a significant decrease in overall survival in cases with
high expression of both SOX2 and GLI1 (p= 0.0213)
(Fig. 1J). In addition, the subgroup of melanoma cases with
high expression of both SOX2 and GLI1 exhibited lower
frequency of KRAS mutations (0.0182 vs. 0.292) and
higher frequency of PTEN mutations (0.1272 vs. 0.0414)
(Supplementary Fig. 4b), although the relevance of this
finding needs further investigation.
BRD4 is required for binding and transactivation of
GLI1 promoter by SOX2
The identified SOX2-consensus sequence within GLI1
promoter is close to a DNA element showing enrichment of
BRD4 [17, 18]. Since BRD4 is highly expressed in mela-
noma (Supplementary Fig. 4a) [19–22], we investigated its
requirement in the binding and transactivation of GLI1
promoter by SOX2. Silencing of BRD4 using two inde-
pendent shRNAs (LV-shBRD4.1 and LV-shBRD4.2)
strongly decreased the expression of GLI1 at both mRNA
and protein level in melanoma cells (Fig. 2A, B). ChIP-
qPCR of BRD4 confirmed occupancy of BRD4 at the GLI1
promoter, with approximately 16-fold enrichment in
GLI1 signal over ChIP with non-specific IgG (p < 0.05),
which was abrogated upon pharmacological blockade of
BRD4 activity with the pan-selective BET inhibitor JQ1
(Fig. 2C). JQ1 also led to a significant decrease of GLI1
transactivation, consistently to the robust decrease of GLI1
mRNA and protein (Fig. 2D–F). Our data are in line with
previous reports showing that inhibition of BRD4 restrains
HH/GLI-dependent growth of medulloblastoma, BCC,
breast and pancreatic cancers [17, 18, 23, 24].
Although BET inhibitors show limited selectivity due to
the inability to discriminate between the BD1 and BD2
bromodomains across the BET family members, which are
overexpressed in melanoma cells, we confirmed our data
with the recently developed MZ1, a PROTAC chimera that
links JQ1 to a ligand for the E3-ubiquitin ligase VHL,
rapidly inducing enduring and preferential removal of
BRD4 over BRD2 and BRD3 [13, 14]. Indeed,
BRD4 silencing nullified the effect of MZ1 on cell viability,
but partially desensitized that of JQ1, confirming the higher
specificity of MZ1 (Fig. 2G). To prove the selectivity of
MZ1 toward BRD4 vs. BRD2 and BRD3, we monitored
expression levels of BRD proteins in SSM2c, A375 and
MeWo cells treated with increasing doses of MZ1. While
MZ1 treatment induced a strong reduction (more than 50%)
of BRD4 protein expression starting from 0.05 to 0.1 μM in
all three cell lines, the expression of BRD2 and BRD3
proteins was affected only at higher doses (Supplementary
Fig. 5a). Further, silencing of BRD2 or BRD3 did not
change the effect of MZ1 on melanoma cell viability
compared to control cells (Supplementary Fig. 5b–e). Taken
together, our data indicate that MZ1 induces preferential
degradation of BRD4 over BRD2 and BRD3. Notably,
MZ1 led to a significant reduction of GLI1 transactivation
with overall decrease of GLI1 levels, paralleling the effects
observed after genetic silencing of BRD4 (Fig. 2H, I).
As BRD4 interacts with acetyl-lysine residues of histone
3 (H3) and histone 4 (H4) functioning as transcriptional
coactivator [25], we next investigated whether BRD4
functions as SOX2-cofactor. We performed protein co-
immunoprecipitation (Co-IP) of SOX2 and BRD4 in pre-
sence of DNase I, or ethidium bromide to unwind the DNA
helix. Western blot showed that SOX2 and BRD4 proteins
co-immunoprecipitated despite treatments (Fig. 3A), sug-
gesting that interaction between these two proteins may be
direct and independent from their interaction with neigh-
boring regions of DNA. We then addressed the requirement
of BRD4 for SOX2-induced transcriptional activation of
GLI1. Silencing of BRD4, as well as its pharmacological
depletion with MZ1 or catalytic inhibition through JQ1,
prevented SOX2-binding to GLI1 promoter (Fig. 2B, C),
without altering SOX2 expression in melanoma cells
(Supplementary Fig. 6). Both genetic and pharmacological
inhibition of BRD4 led to a significant decrease of the
luciferase activity in presence of the −584/−133 bp frag-
ment of GLI1 promoter containing a functional SOX-BS
Fig. 1 SOX2 binds to and transactivates GLI1 promoter. A ChIP-
qPCR of SOX2 occupancy at GLI1 promoter (n= 3). Schematic
representation of GLI1 promoter with the position of ChIP probes (red
double arrowhead) and consensus SOX2 binding sites (BS) (vertical
slashes) relative to the transcription starting site (TSS). B,C qPCR (B)
and Western blot (C) in melanoma cells transduced with LV-c or LV-
shSOX2.1, showing that SOX2 silencing inhibits GLI1 expression in
melanoma cells (n= 3). HSP90 was used as loading control in (C).
D Dual-luciferase assay in SSM2c melanoma cells showing the effect
of SOX2 modulation on the transactivation of a GLI-BS luciferase
reporter (left). Silencing of GLI1, but not of SMO, is able to counteract
SOX2-induced GLI-BS transactivation (right) (n= 4). E Dual-
luciferase assay in SSM2c cells transfected with three different GLI1
promoter fragments (−829/+111, −829/−133,−584/−133). It shows
that SOX2 is able to transactivate all three promoter regions (n= 5).
F Putative SOX2-BS in the −829 bp GLI1 promoter with mutagenized
sites (Mut1, Mut2 and Mut3). G Dual-luciferase assay in SSM2c cells
showing that Mut2 prevented SOX2 from transactivating the −584 bp
fragment of the GLI1 promoter (n= 3). H Pearson correlation analysis
of GLI1 and SOX2 mRNA in normal human epidermal melanocytes
(NHEM, blue) and human melanoma cells (red) (p= 0.036). I Scatter
plot of GLI1/SOX2 expression, where each data point represents an
individual case. Graph was generated in Prism using data from the
TCGA Melanoma (SKCM) dataset. Kruskal–Wallis test was used to
compare four groups (p < 0.0001). J Overall Survival curve of cases
from the SKCM Melanoma dataset in TCGA. Red line represents
cases that have high expression of both SOX2 and GLI1, and blue line
represents cases that do not. The plot was generated using Xena
software. The two curves were compared using Log-rank test (p=
0.0213). In (A, B, D, E, G) data are presented as mean ± SEM.
P values were calculated by two-tailed unpaired Student’s t test (A, B,
D left panel, E, G) or one-way ANOVA with Tukey’s test (D, right
panel). *, p < 0.05; **, p < 0.01; ***, p < 0.0001; ns not significant.
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(wt) but failed to affect that of the promoter in which the
SOX-BS was disrupted (Mut2) (Fig. 3D and E). To confirm
this, genetic silencing of SOX2 almost completely abrogated
the effect of BRD4 or MZ1 on the transactivation of GLI1
promoter (Fig. 3F, G). However, we cannot exclude that
BRD4 could affect GLI1 transcription by binding to addi-
tional regulatory regions of GLI1 (i.e., distal enhancers).
Indeed, BRD4 silencing led to decreased GLI1 expression
even in absence of SOX2, albeit to a lesser extent (Supple-
mentary Fig. 7). Altogether these data indicate that BRD4
acts as a SOX2 cofactor to induce GLI1 transcriptional
activation. To further support the relevance of this regulation
during melanoma progression, single-cell analysis in cells
derived from normal melanocytes and from a melanoma
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brain metastasis PDX model (M15) showed co-expression of
SOX2, BRD4 and GLI1 in a subgroup of metastatic mela-
noma cells but not in melanocytes (Fig. 3H).
The SMO antagonist MRT-92 synergizes with the
BRD4 degrader MZ1 to inhibit melanoma cell
growth
As specific inhibitors for SOX2 are currently not available,
we investigated the therapeutic efficacy of combined SMO
and BRD4 targeting. Co-administration of MRT-92 and
MZ1 or JQ1 led to marked cytotoxic activity compared to
single agents in melanoma cells grown either as a mono-
layer or as three-dimensional (3D) cell cultures (Fig. 4A, B;
Supplementary Fig. 8). The isobologram summarizes the
combination index (CI) at the IC50 when the SMO inhibitor
MRT-92 and the BRD4-degrader MZ1 were combined,
showing a moderate synergistic anti-proliferative effect (CI
< 1) in melanoma cells independently of their BRAF,
NRAS, and NF1 mutational status (Fig. 4C, D). Western
blot analysis of GLI1 confirmed that the two small mole-
cules are variably effective in decreasing GLI1 protein
level, and almost completely abrogated GLI1 when used in
combination (Fig. 4E). MRT-92/MZ1 combination also
appeared to induce signs of DNA damage, as shown by
cleavage of poly ADP-ribose polymerase-1 (PARP-1) and
increased phosphorylation of ɣH2AX (Fig. 4E). To inves-
tigate the durability of the effects of the drug combination,
SSM2c, MeWo and A375 cells were treated with con-
centrations of MRT-92 and MZ1 that displayed a strong
synergistic effect when combined, and cell growth was
monitored up to 7 days without any additional drug
administration. Growth curves showed that while single
treatments barely affected melanoma cell growth, their
combination almost abrogated it, indicating the long-lasting
effect of the drug combination in inhibiting melanoma cell
growth (Fig. 4F). Importantly, ectopic expression of GLI1
rescued the effect of MRT-92 and MZ1 combination in
reducing melanoma cell viability (Fig. 5).
Combined targeting of SMO and BRD4 suppresses
self-renewal of melanoma stem-like cells
We have previously shown that the HH/GLI signaling is
critical for the maintenance of melanoma cancer stem-like
cells (CSC) [26] whose occurrence has been shown to cor-
relate with chemotherapeutic resistance, relapse and metas-
tasis in several tumor types [27]. Other studies reported a role
for BRD4 in promoting CSC self-renewal [28, 29]. Thus, we
tested whether combined inhibition of SMO and blockade of
BRD4 may synergize in reducing self-renewal ability of
melanoma CSCs. Combined treatment with IC50 concentra-
tions of MRT-92 and MZ1 significantly reduced primary
sphere formation and suppressed their ability to self-renew
and form secondary spheres (Fig. 6A, B). Secondary spheres
were also reduced in size (Fig. 6C), suggesting an effect on
proliferation or survival of committed or more-differentiated
progenitors that make up the bulk of spheres.
To further address the effect of this drug combination
on melanoma CSC maintenance, we performed limiting
dilution assays (LDA) in SSM2c cells plated at varying
densities. Results indicated that untreated control cells
formed spheres at 250, 100, 75, 50 and 10 cells/well, with
an estimated sphere-forming frequency of 1/52.5. Con-
versely, treatment with MRT-92 or MZ1 alone decreased
sphere-forming capacity, dropping to 1/151.4 for MRT-92
(p < 0.0001) or 1/203.7 for MZ1 (p < 0.0001), whilst their
combination almost abrogated sphere formation already at
75 cells/well dilution, with an estimated frequency of 1/
638.3 (p < 0.0001) (Fig. 6D). Altogether, these data indi-
cate that targeting both SMO and BRD4 drastically
reduces the ability of melanoma-spheres to self-renew
in vitro, supporting their efficacy against melanoma CSCs.
Combined targeting of SMO and BRD4 shows a
significant in vivo antitumor activity
To investigate the efficacy of the combined blockade of
SMO and BRD4 in vivo, we assessed the effects of the drug
combination in the growth of orthotopic A375 melanoma
xenografts (Fig. 7A). No significant tumor growth inhibi-
tion was observed in animals treated with either MRT-92
(T/C% of 53.8) or MZ1 (T/C% of 47.7) as single agents,
whereas a greater antitumor effect was achieved when
combined (T/C% of 16.8) (Fig. 7B, C). Consistently, GLI1
expression was completely abrogated only in tumors treated
Fig. 2 BRD4 regulates GLI1 transcription in melanoma. A qPCR
of BRD4 and GLI1 after BRD4 silencing with two independent
shRNAs. B Western blot analysis of BRD4 and GLI1 in melanoma
cells transduced as indicated. HSP90 was used as loading control.
C ChIP-qPCR of BRD4 occupancy on GLI1 promoter in SSM2c
treated with vehicle (DMSO) or 100 nM JQ1 for 18 h. Data are pre-
sented as % of input and are expressed as fold over IgG control ± SEM
(n= 3). D Quantification of dual-luciferase assay in SSM2c melanoma
cells treated with DMSO or increasing concentrations of JQ1. Relative
luciferase activities were firefly/Renilla ratios, with the level induced
by the vehicle equated to 1 (n= 3). E qPCR of GLI1 in three mela-
noma cell lines treated with DMSO or increasing concentrations of
JQ1. F WB of BRD4 and GLI1 in melanoma cells treated with JQ1 as
indicated. HSP90 was used as loading control. G Histogram of mel-
anoma cell viability in cells transduced with LV-c or LV-shBRD4 and
treated with DMSO or increasing concentrations of JQ1 or MZ1
(n= 3). H Quantification of dual-luciferase assay in SSM2c cells
treated with DMSO or increasing concentrations of MZ1 (n= 3).
I WB of BRD4 and GLI1 in melanoma cells treated with DMSO or
increasing concentrations of MZ1. HSP90 was used as loading control.
Data are presented as mean ± SEM. P values were calculated by two-
tailed unpaired Student’s t test (A, D, E, G, H) or one-way ANOVA
with Tukey’s test (C). *, p < 0.05; **, p < 0.01; ***, p < 0.0001.
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Fig. 3 BRD4 acts as a SOX2 cofactor in GLI1 transcriptional
activation. A Co-IP of SOX2 and BRD4 in SSM2c lysates untreated
or exposed to 25 U/ml DNase or 200 μg/ml ethidium bromide (EtBr).
Input was 5%. B ChIP-qPCR of SOX2 occupancy at GLI1 promoter in
SSM2c LV-c treated with vehicle (DMSO), JQ1 (100 nM) or MZ1
(125 nM), or LV-shBRD4. C Western blot of BRD4, SOX2 and GLI1
in SSM2c cells transduced with LV-c or LV-shBRD4 (upper panel) or
treated with DMSO, JQ1 or MZ1 for 24 h (lower panel). D–E Dual-
luciferase assay in SSM2c cells transduced with LV-c or LV-shBRD4
(D) or treated with increasing concentrations of MZ1 (E). It shows that
Mut2 prevents BRD4 from transactivating the −584/−133 fragment of
GLI1 promoter in absence of a functional SOX2-BS (Mut2) (n= 3).
F–G Dual-luciferase assay in SSM2c cells transduced with LV-c or
LV-shBRD4 in presence or absence of SOX2 (F) or treated with
increasing concentrations of MZ1 in presence or absence of SOX2 (G)
as indicated (n= 3). H Venn diagram showing that the distribution of
cells expressing GLI1, SOX2, and/or BRD4 is different between nor-
mal human neonatal epidermal melanocytes (NHEM, left) and patient-
derived melanoma xenografts (M15, right). Single cell RNA-seq data
were filtered to the 80th percentile of high gene expression, and
number of cells expressing one, two, or all three of these genes was
quantified. The green circle represents number of cells expressing
BRD4, the blue circle represents SOX2, and the red circle represents
GLI1. The cutoff values for expression representing the 80th percentile
in SOX2, GLI1, and BRD4 were 0.06783216, 0.6914666, and
0.6897033, respectively. In (B, D, E, F, G), data are presented as
mean ± SEM. P values were calculated by one-way ANOVA with
Tukey’s test (B) or two-tailed unpaired Student’s t test (D–G).
*, p < 0.05; **, p < 0.01; ***, p < 0.0001; ns not significant.
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Fig. 4 Co-targeting SMO and BRD4 reduces melanoma growth
in vitro. A Histograms of melanoma cell viability after treatment with
DMSO, MRT-92 (SSM2c and A375, 250 nM; MeWo, 300 nM), MZ1
(SSM2c and MeWo, 125 nM; A375 250 nM) or their combination for
72 h. B Histograms of 3D spheroid size at the optimized seeding
densities (T0) or after 72 h of treatment as indicated in (A). Scale bars
= 200 µm. C Normalized IC50 isobologram showing synergistic
effects of MRT-92 and MZ1 combination. D Table showing the
combination index (CI) values at the IC50 of MRT-92 and MZ1 with
melanoma cell mutational status. E Representative WB of BRD4,
GLI1, PARP-1 and γ-H2AX cells treated for 72 h as indicated (n= 3).
HSP90 was used as loading control. In (A, B) data are presented as
mean ± SEM. F Growth curves of melanoma cells treated for 7 days
with MRT-92, MZ1 or combination at the following concentrations:
SSM2c: MRT-92 at 250 nM and MZ1 at 125 nM; MeWo: MRT-92 at
300 nM and MZ1 at 125 nM; A375: MRT-92 at 250 nM and MZ1 at
250 nM. Data are expressed as fold percentage of vehicle (DMSO) ±
SEM (n= 3). P values were calculated by one-way ANOVA with
Tukey’s test (A, B, F). *, p < 0.05; **, p < 0.01; ***, p < 0.0001; ns
not significant.
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with the drug combination (Fig. 7D). Treatment with single
agents or their combination was well tolerated in mice,
without significant signs of toxicity. Throughout treatment,
mice were well-conditioned with a body condition score
[30] BC3 for all groups. Altogether, these results demon-
strate that co-administration of MRT-92 and MZ1 improves
the effect of single treatments against melanoma growth
in vitro and in vivo.
Discussion
Constitutive activation of GLI1 is associated with several
types of cancer. Clinical trials based on the administration
of SMO antagonists have demonstrated effectiveness in
HH-driven tumors, such as BCC and medulloblastoma;
however, the therapeutic efficacy of SMO inhibitors may
not be effective in tumors having non-canonical activation
of GLI1. Although many efforts in developing specific GLI
inhibitors, good candidates for clinical trials are still lack-
ing. Therefore, molecular inhibitors of GLI1 that directly
affect its transcription by breaking the positive feedback
loop may reveal very useful. In this study we show that
SOX2 acts in a transcriptional complex with the epigenetic
reader BRD4 to directly regulate GLI1 transcription,
providing a novel mechanism of non-canonical SMO-
independent activation of GLI1. The findings that MZ1 and
MRT-92 combination completely abrogates GLI1 expres-
sion and that ectopic expression of GLI1 is able to rescue
the inhibition of melanoma cell growth induced by the drug
combination, suggest that GLI1 is the main molecular and
functional target of the SOX2-BRD4 transcriptional com-
plex. Therefore, as specific inhibitors of SOX2 are currently
not available, targeting the SOX2-BRD4 transcriptional
complex could be effective to curtail HH/GLI pathway
downstream of SMO (Fig. 7E).
The existence of a direct regulation of SOX2 by GLI1
was previously described in melanoma, where both SOX2
and HH/GLI signaling are required for melanoma CSC
self-renewal [26, 31]. This modulation has been asso-
ciated with drug resistance in other types of cancer. For
instance, GLI1-mediated regulation of SOX2 enhances
CSC self-renewal and confers resistance to EGFR inhi-
bitors in non-small cell lung cancer [32]. Accordingly,
activation of the GLI-SOX2 axis is involved in gemcita-
bine resistance in pancreatic cancer [33]. Recently, a
reciprocal regulation between SOX2 and GLI1 has been
described to fuel aberrant glycosylation/sialylation during
melanoma progression [34]. Altogether, these reports and
the present study highlight the importance and the
Fig. 5 GLI1 overexpression rescues the effects of combined inhi-
bition of SMO and BRD4. A Western blot of BRD4 and GLI1 in
melanoma cells transduced with LV-c or LV-GLI1 after treatment with
MRT-92, MZ1 or their combination for 72 h. HSP90 was used as
loading control. B Cell viability of SSM2c, A375 and MeWo cells
transduced with LV-c or LV-GLI1 after 72 h of treatment with MRT-
92, MZ1 or combination at the following concentrations: SSM2c:
MRT-92 at 250 nM and MZ1 at 125 nM; A375: MRT-92 at 250 nM
and MZ1 at 250 nM; MeWo: MRT-92 at 300 nM and MZ1 at 125 nM.
Data are expressed as fold change of vehicle (DMSO) ± SEM. (n= 3).
P values were calculated by one-way ANOVA with Tukey’s test.
*, p < 0.05; **, p < 0.01.
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biological relevance of the mutual regulation between
SOX2 and GLI transcription factors in cancer.
Previous studies have identified BET proteins as epigenetic
regulators of HH transcriptional output, in particular of Gli1
and Gli2, and demonstrated that HH-driven tumors respond to
JQ1 and I-BET151 [17, 18]. Chromatin immunoprecipitation
(ChIP) coupled with DNA-sequencing have revealed highly
asymmetric binding pattern of BRD4, with most chromatin
bound BRD4 localized to super-enhancer elements important
for cell-type specification and oncogenesis [35]. Whether
super-enhancers are positioned over GLI promoters is still
unknown, although our and other studies suggest that BRD4
occupies GLI1 promoters [17, 18]. Previous reports have
shown that BRD4 plays a critical role in melanoma
[19, 20, 22, 36], representing a promising therapeutic target.
However, the translational potential of pan-selective BET
inhibitors used in these studies is limited. Indeed, the lack of
discrimination between the BD1 and BD2 bromodomains
across the BET family members could limit their selectivity
and pose the threat of undesired side effects in clinical settings.
Further, BET inhibitors such as JQ1 show a very short half-
life, and the concentrations required to mediate single agent
Fig. 6 Combined targeting of SMO and BRD4 inhibits melanoma
sphere self-renewal and survival. A Primary (white bars) and sec-
ondary (black bars) sphere formation assays from SSM2c, MeWo and
A375 melanoma cells treated with MRT-92, MZ1 or combination
(n= 3). B Representative phase-contrast images of secondary SSM2c,
MeWo and A375 spheres as indicated in (A). Scale bar= 200 μm.
C Size of secondary SSM2c, MeWo and A375 spheres treated as
indicated. D Limiting dilution assays in SSM2c spheres. The observed
average of sphere-forming frequency is shown, with the expected
range reported below. In (A, C) data are presented as mean ± SEM.
P values were calculated by one-way ANOVA with Tukey’s test.
*, p < 0.05; **, p < 0.01; ***, p < 0.0001 vs. control.
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activity exceed physiologic safety levels in vivo [37]. The
BRD4 degrader MZ1 potently and rapidly induces preferential
removal of BRD4 over BRD2 and BRD3, and has shown high
efficacy in ovarian and triple-negative breast cancer in vivo
[38]. The activity of MZ1 is dependent on binding to VHL but
is achieved at a sufficiently low concentration not to induce
stabilization of the VHL substrate HIF-1α [13].
Here we show that co-targeting BRD4 and SMO elicits a
significant antitumor activity in melanoma, including a
drastic reduction of 2D and 3D melanoma cell growth and
Fig. 7 Efficacy of MRT-92 and MZ1 combination in vivo.
A Schematic illustration of treatment schedule. B In vivo orthotopic
tumor growth of A375 cells in athymic nude mice. At tumor appear-
ance mice were randomized in four groups and treated i.p. with vehicle
alone, MRT-92 (15 mg/Kg, BID), MZ1 (100 mg/Kg, QD), or combi-
nation (n= 7 for each group). C Table shows percentage of tumor
volume reduction in treated groups compared to vehicle-treated group
(% T/C ratio). D Dot plot quantification of GLI1 expression by qPCR
in A375 xenografts (n= 5 for each group). Data are presented as mean
± SEM. P values were calculated by ANOVA with Tukey’s test (B) or
two-tailed unpaired Student’s t test (D). *, p < 0.05; **, p < 0.01; ns
not significant. E Schematic representation of canonical and non-
canonical HH signaling and their inhibition by MRT-92 and MZ1.
Left, non-canonical activation of GLI1 in melanoma: SOX2 and BRD4
form a complex, and BRD4, by interacting with acetylated histones in
the proximal region of the GLI1 promoter, induces RNA polymerase 2
activity and transcriptional activation of GLI1. Right, the SMO
antagonist MRT-92 inhibits canonical HH signaling, whereas MZ1
induces BRD4 degradation with consequent inhibition of GLI1
transcription.
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melanoma stem cell-like self-renewal. Notably, the efficacy
of this combinatorial treatment in melanoma cells is not
influenced by BRAF, NRAS or NF1 mutational status,
opening the possibility of using these compounds to treat
melanoma expressing high levels of SOX2 and GLI1 irre-
spectively to their mutational status. This combinatorial
treatment synergizes in inducing signs of DNA damage in
melanoma cells, consistently with the role of BRD4 in
promoting DNA repair [39], and with previous studies
pointing to the induction of DNA damage following phar-
macological inhibition of the HH/GLI signaling [10, 40].
Given that the efficacy of many antitumor agents relies on
their ability to bypass DNA damage checkpoints with
subsequent apoptosis [41], our findings could provide a
valid alternative strategy to the current standard therapies.
The in vitro synergism translates into a marked antitumor
activity in an orthotopic melanoma xenograft model. Indeed,
the combination of MRT-92 and MZ1 almost completely
abrogated in vivo tumor growth, despite the limited effect of
single agents. Our data also indicate that SMO and BRD4
blockade is well tolerated in mice and does not cause any
apparent side effect. Dual blockade of SMO and BRD4
might also contribute to prevent resistance to pan-selective
BET inhibitors such as JQ1, because resistance to JQ1 can be
mediated by GLI2-dependent upregulation of cMYC and
targeting GLI2 restores JQ1 sensitivity in pancreatic cancer
[42]. In addition, since BRD4 has been shown to enhance the
escape of cancer cells from immunosurveillance through the
regulation of the programmed death 1 (PD-1)/PD-L1
immune checkpoint [43–45], inhibition of BRD4 holds the
potential to elicit an antitumor immune response. At this
regard, the next-generation BET inhibitor PLX51107 was
reported to delay melanoma growth in a syngeneic melanoma
model by eliciting effects on anti-tumor CD8+ T cells [46].
In conclusion, in this study we provide evidence of a
novel mechanism of non-canonical SMO-independent
activation of GLI1 by the SOX2-BRD4 axis and describe
the efficacy of a combinatorial treatment with a novel SMO
inhibitor and the PROTAC-derived BRD4 degrader MZ1 in
melanoma. The existence of a reciprocal regulation between
SOX2 and GLI1 [31] (this study), which is involved in the
transcriptional activation of genes involved in melanoma
progression [34], highlights the therapeutic potential of
targeting this axis to treat a subset of advanced melanomas
expressing high levels of SOX2 and GLI1.
Materials and methods
Cell cultures
Normal human epidermal melanocytes (NHEM) and human
melanoma cell lines A375, SK-Mel-2, SK-Mel-5, SK-Mel-28
and MeWo were obtained from ATCC, whereas A2058, 501-
Mel and SK-Mel-197 were provided by Dr. Laura Poliseno
(CNR, Pisa, Italy). Patient-derived metastatic melanoma cells
SSM2c and M51 were already described [26, 47]. Cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM),
containing 10% fetal bovine serum (FBS), 1% penicillin-
streptomycin solution (Lonza, Thermo Fisher Scientific) and
1% Glutamine (Lonza). All cells were authenticated by DNA
fingerprinting analysis and regularly tested for potential
Mycoplasma contamination.
Compounds
The SMO inhibitor MRT-92 was already described [10]. The
pan-BET inhibitor JQ1 (Catalog No. S7110, purity ≥99%)
was purchased from Selleckchem (Munich, Germany). The
PROTAC degrader MZ1 was synthesized in ~1 g scale by
optimizing the previously described synthetic route [13].
Quantification of the effect of the treatments
Crystal violet assay after 72 h treatment was used to mea-
sure cell proliferation using a plate reader (Victor X5,
PerkinElmer). To obtain the response of cell lines to the
combination of MRT-92 with either MZ1 or JQ1, cells were
treated simultaneously with increasing concentrations of
the two molecules. Results were examined by isobologram
analysis with the Chou-Talalay Method by the Compusyn
software [48] program to calculate the efficacy (CI) of the
experimental points.
Plasmids and viral production
Lentiviruses for gene silencing were produced in HEK-293T
as previously described [10]. shRNA vectors used were:
pLKO.1-puro (scramble, LV-c) (Addgene #8453), pLKO.1-
puro-shSOX2.1 (LV-shSOX2.1) targeting the 3′ untranslated
region of SOX2 (targeting sequence 5′-CTGCCGAGAATC
CATGTATAT-3′), pLKO.1-puro-shSOX2.2 (LV-shSOX2.2)
targeting the coding region of SOX2 (targeting sequence 5′-
CAGCTCGCAGACCTACATGAA-3′) [31], pLKO.1-puro-
shBRD4.1 (LV-shBRD4.1) targeting the coding region of BR
D4 (targeting sequence 5′- CCTGGAGATGACATAGTCTT
A-3′) and pLKO.1-puro-shBRD4.2 (LV-shBRD4.2) targeting
the 3′ untranslated region of BRD4 (targeting sequence 5′-
GCCAAATGTCTACACAGTATA-3′), pLKO.1-puro-shBR
D2 (LV-shBRD2) targeting the 3′ untranslated region of
BRD2 (targeting sequence 5′-CCCTTTGCTGTGACACTT
CTT-3′), and pLKO.1-puro-shBRD3 (LV-shBRD3) targeting
the 3′ untranslated region of BRD3 (targeting sequence
5′-CCAAGGAAATGTCTCGGATAT-3′). Lentiviruses for
gene overexpression were produced in HEK-293T by co-
transfection of CSGW vector, CSGW-SOX2 (cloned into the
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BglII-NotI restriction sites of CSGW vector using the fol-
lowing primers: SOX2-F 5′-ATGTACAACATGATGG
AGACGG-3′ and SOX2-R 5′- TCACATGTGTGAGAGGG
GC-3′) or CSGW-GLI1 (cloned into the BglII-NotI restriction
sites of CSGW vector using the following primers: GLI1-F
5′-ATGTTCAACTCGATGACCCCAC-3′ and GLI1-R 5′-T
TAGGCACTAGAGTTGAGGAA-3′) with pCMV-dR8.91
packaging plasmid and pMD2.G envelope plasmid (Addgene
#12259).
Chromatin immunoprecipitation
ChIP experiments were performed as previously described
[34]. Primer sequences are listed in Supplementary Table 1.
Quantitative RT-PCR
Quantitative real-time PCR was performed as already
described [34].
Mutagenesis and luciferase assay
Three fragments of GLI1 promoter (−829/+111 bp, −829/
−133 bp and−584/−133 bp) were PCR amplified with KOD
hot start DNA polymerase (Merck Millipore) and cloned into
the pGL3Basic vector (Promega) using NheI-HindIII sites, to
generate −829/+111 bp, −829/−133 bp and −584/−133 bp
GLI1 prom-luc reporters. Mutations of GLI1 prom −584/
−133 reporter were introduced using QuickChange II (Agi-
lent Technologies). All primers are listed in Supplementary
Table 2. GLI1 promoter reporters were used in combination
with Renilla luciferase pRL-TK reporter vector (Promega) to
normalize luciferase activities. Luminescence was measured
using the Dual-Glo Luciferase Assay System (Promega) and
the GloMax 20/20 Luminometer (Promega).
Single-cell RNA sequencing
Melanoma patient-derived xenograft line M15 was derived
from brain metastasis of Mayo Clinic patients under proper
IRB and IACUC protocols. Normal human neonatal epi-
dermal melanocytes (Lifeline Cell Technology) were used
as a control. Single-cell RNA sequencing was performed at
Mayo Clinic’s Genome Analysis Core Facility as already
described [34]. Monocle3 [49] was used to analyze the
single-cell RNA-seq dataset. Data are available from GEO
under accession number GSE159597.
Western blot and co-immunoprecipitation
Western blot and Co-IP were performed as already descri-
bed [34]. List of primary antibodies is reported in Supple-
mentary Table 3.
Three-dimensional (3D) tumor-sphere assay
For 3D tumor-sphere generation, melanoma cells were
plated in 1% FBS at optimal seeding densities (SSM2c
1500 cells/well, MeWo 3000 cells/well; A375 1500
cells/well) in ultra-low attachment (ULA) 96-well round
bottom plates, centrifuged at 800 rpm for 3 min, allowed
to form a three-dimensional structure within 24 h and
photographed (T0). Spheroids were then treated with
vehicle (DMSO), MRT-92 (250 nM for SSM2c and
A375; 500 nM for MeWo), MZ1 (125 nM for MeWo;
250 nM for SSM2c and A375), JQ1 (100 nM for SSM2c
and MeWo; 500 nM for A375) or combinations at the
indicated concentrations for 72 h. Photos were executed
with a LEICA DFC450C microscope with 4X objective
lens, and both length and width of each spheroid mea-
sured using Image J, averaged and then normalized to
that of T0.
Melanoma-spheres and limiting dilution assay
SSM2c, MeWo and A375 melanoma-spheres were cul-
tured in human embryonic stem cell medium supple-
mented with 4 ng/ml basic fibroblast growth factor. For
primary sphere-formation and self-renewal, cells were
plated in 12-well plates (Corning) at 1 cell/μl dilution, and
allowed to form over 24 h before pharmacologic manip-
ulation with vehicle (DMSO), MRT-92 (250 nM for
SSM2c and A375; 500 nM for MeWo), MZ1 (125 nM for
MeWo; 250 nM for SSM2c and A375), JQ1 (100 nM
for SSM2c and MeWo, 500 nM for A375) or combinations
for 96 h. Primary spheres were dissociated into single cells
and re-plated at 1 cell/μl dilution in ULA 12-well plates.
After 1 week, spheres were photographed and counted
with a LEICA DFC450C microscope with 4X objective
lens, and both length and width of each sphere were
measured using Image J and averaged.
For limiting dilution assay, cells were plated at 250, 100,
75, 50 or 10 cell/well in sphere conditions in flat 96-well
plates, and 32 wells per condition were assessed. Wells
were scored positive (≥1 sphere/well) or negative
(0 spheres/well) for sphere formation after 10 days in cul-
ture. Sphere forming frequency and statistics were calcu-
lated using ELDA software [50].
Orthotopic melanoma xenografts
A375 melanoma cells were resuspended in Matrigel
(Beckton Dickinson)/DMEM 1/1 and inoculated sub-
cutaneously into the right lateral flank of adult (8 weeks)
female athymic nude mice (Foxn1 nu/nu) (Charles River
Laboratories) (10.000 cells/injection). Once tumors were
palpable (≤100 mm3), mice were randomized in four
Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the. . .
groups and treated i.p. with MRT-92 (15 mg/Kg, BID),
MZ1 (100 mg/Kg, QD), the combination of MRT-92
and MZ1 or the vehicle alone for 10 days. Both drugs
were dissolved in vehicle (30% 2-hydroxypropyl-
β-cyclodextrin) (Sigma-Aldrich). Subcutaneous tumor
size was measured blindly three times a week with a
caliper and tumor volume was calculated using the for-
mula: V=W2 × L × 0.5, where W and L are tumor width
and length, respectively. The Body Condition Scoring was
used to assess mice health status [30]. No animals were
excluded from the analysis. No statistical methods were
used for sample size estimation. Mouse maintenance and
animal experiments were performed according with the
study protocol approved by the local Swiss Cantonal
Veterinary Authority (No. TI-08-2019).
The Cancer Genome Atlas analysis
The University of California Santa Cruz Xena platform was
used to visualize and analyze transcriptomic and survival
data from 477 cases in the TCGA melanoma (SKCM)
cohort [51].
Statistical analysis
Data represent mean ± SD or mean ± SEM values calcu-
lated on at least three independent experiments. No sta-
tistical methods were used for sample size selection. The
estimate of variation within each group was similar.
P values were calculated using Student’s t test (two
groups) or one-way analysis of variance (ANOVA) (more
than two groups). A two-tailed value of p < 0.05 was
considered statistically significant. *, p < 0.05; **, p <
0.01, ***, p < 0.0001.
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